接受泽布替尼治疗的患者对 COVID-19 疫苗接种免疫反应的前瞻性综合分析。
Prospective comprehensive profiling of immune responses to COVID-19 vaccination in patients on zanubrutinib therapy.
作者信息
Nguyen Thi H O, Lim Chhay, Lasica Masa, Whitechurch Ashley, Tennakoon Surekha, Saunders Natalie R, Allen Lilith F, Rowntree Louise C, Chua Brendon Y, Kedzierski Lukasz, Tan Hyon-Xhi, Wheatley Adam K, Kent Stephen J, Karapanagiotidis Theo, Nicholson Suellen, Williamson Deborah A, Slavin Monica A, Tam Constantine S, Kedzierska Katherine, Teh Benjamin W
机构信息
Department of Microbiology and Immunology University of Melbourne Parkville Victoria Australia.
Department of Infectious Diseases Peter MacCallum Cancer Centre Melbourne Victoria Australia.
出版信息
EJHaem. 2023 Jan 20;4(1):216-220. doi: 10.1002/jha2.639. eCollection 2023 Feb.
Zanubrutinib-treated and treatment-naïve patients with chronic lymphocytic leukaemia (CLL) or Waldenstrom's macroglobulinaemia were recruited in this prospective study to comprehensively profile humoral and cellular immune responses to COVID-19 vaccination. Overall, 45 patients (median 72 years old) were recruited; the majority were male (71%), had CLL (76%) and were on zanubrutinib (78%). Seroconversion rates were 65% and 77% following two and three doses, respectively. CD4 and CD8 T-cell response rates increased with third dose. In zanubrutinib-treated patients, 86% developed either a humoral or cellular response. Patients on zanubrutinib developed substantial immune responses following two COVID-19 vaccine doses, which further improved following a third dose.
在这项前瞻性研究中，招募了接受泽布替尼治疗和未接受过治疗的慢性淋巴细胞白血病（CLL）或华氏巨球蛋白血症患者，以全面分析对新冠疫苗接种的体液和细胞免疫反应。总体而言，招募了45名患者（中位年龄72岁）；大多数为男性（71%），患有CLL（76%）且正在接受泽布替尼治疗（78%）。两剂和三剂接种后的血清转化率分别为65%和77%。第三剂接种后，CD4和CD8 T细胞反应率有所提高。在接受泽布替尼治疗的患者中，86%产生了体液或细胞反应。接受泽布替尼治疗的患者在接种两剂新冠疫苗后产生了显著的免疫反应，第三剂接种后进一步增强。
Zotero 插件